Detailed information for compound 1602308

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 389.407 | Formula: C21H19N5O3
  • H donors: 2 H acceptors: 4 LogP: 2.48 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: Cc1ccc(cc1)C(=O)Nc1cccc(c1)c1[nH]c2c(n1)n(C)c(=O)n(c2=O)C
  • InChi: 1S/C21H19N5O3/c1-12-7-9-13(10-8-12)19(27)22-15-6-4-5-14(11-15)17-23-16-18(24-17)25(2)21(29)26(3)20(16)28/h4-11H,1-3H3,(H,22,27)(H,23,24)
  • InChiKey: JJYXEJHZEXKXAT-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Mus musculus monoamine oxidase B Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Mycobacterium ulcerans flavin-containing monoamine oxidase AofH Get druggable targets OG5_130722 All targets in OG5_130722
Mycobacterium ulcerans flavin-containing monoamine oxidase AofH Get druggable targets OG5_130722 All targets in OG5_130722
Mycobacterium tuberculosis Probable flavin-containing monoamine oxidase AofH (amine oxidase) (MAO) Get druggable targets OG5_130722 All targets in OG5_130722
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi amine oxidase, flavin-containing family protein monoamine oxidase B 520 aa 485 aa 22.9 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni NADP-specific isocitrate dehydrogenase 0.1751 1 0.5
Trypanosoma brucei isocitrate dehydrogenase, putative 0.1751 1 0.5
Leishmania major isocitrate dehydrogenase [NADP], mitochondrial precursor, putative 0.1751 1 0.5
Echinococcus multilocularis isocitrate dehydrogenase 2 (NADP+) 0.1751 1 0.5
Plasmodium falciparum isocitrate dehydrogenase [NADP], mitochondrial 0.1751 1 0.5
Trypanosoma cruzi isocitrate dehydrogenase, putative 0.1751 1 0.5
Brugia malayi Isocitrate dehydrogenase 0.1751 1 0.5
Echinococcus multilocularis NADP dependent isocitrate dehydrogenase 0.1751 1 0.5
Plasmodium vivax isocitrate dehydrogenase [NADP], mitochondrial, putative 0.1751 1 0.5
Mycobacterium tuberculosis Probable isocitrate dehydrogenase [NADP] Icd1 (oxalosuccinate decarboxylase) (IDH) (NADP+-specific ICDH) (IDP) 0.1751 1 1
Echinococcus multilocularis NADP dependent isocitrate dehydrogenase 0.1751 1 0.5
Trypanosoma cruzi isocitrate dehydrogenase [NADP], mitochondrial precursor, putative 0.1751 1 0.5
Echinococcus granulosus NADP dependent isocitrate dehydrogenase 0.1751 1 0.5
Mycobacterium ulcerans flavin-containing monoamine oxidase AofH 0.0359 0.0178 0.5
Mycobacterium ulcerans flavin-containing monoamine oxidase AofH 0.0359 0.0178 0.5
Toxoplasma gondii isocitrate dehydrogenase 0.1751 1 0.5
Echinococcus multilocularis isocitrate dehydrogenase 0.1751 1 0.5
Trypanosoma brucei isocitrate dehydrogenase [NADP], mitochondrial precursor, putative 0.1751 1 0.5
Echinococcus multilocularis NADP dependent isocitrate dehydrogenase 0.1751 1 0.5
Loa Loa (eye worm) isocitrate dehydrogenase 0.1751 1 0.5
Toxoplasma gondii isocitrate dehydrogenase 0.1751 1 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 14 uM Inhibition of MAO-B in mouse cerebral homogenate using kynuramine as substrate after 30 mins by fluorimetry in the presence of MOA-A inhibitor clorgyline ChEMBL. 22257893
Inhibition (binding) = 41.6 % Inhibition of MAO-B in mouse cerebral homogenate using kynuramine as substrate after 30 mins by fluorimetry in the presence of MOA-A inhibitor clorgyline relative to control ChEMBL. 22257893
Ki (binding) = 2.87 uM Inhibition of MAO-B in mouse cerebral homogenate using kynuramine as substrate after 30 mins by fluorimetry in the presence of MOA-A inhibitor clorgyline ChEMBL. 22257893

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.